Hims & Hers Health (NYSE:HIMS) Trading 5.1% Higher - Should You Buy?

Key Points

• Hims & Hers Health's stock price rose by 5.1% to $46.71, although trading volume was down by 51% compared to the average.
• Several research firms have downgraded the stock, with Zacks Research changing its rating from "strong-buy" to "hold," while Truist Financial reduced its target price from $48.00 to $37.00.
• The company's quarterly earnings showed a 72.6% revenue increase year-over-year, but missed analysts' EPS expectations by $0.01.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) were up 5.1% on Thursday . The stock traded as high as $47.15 and last traded at $46.71. Approximately 16,105,128 shares traded hands during trading, a decline of 51% from the average daily volume of 33,074,004 shares. The stock had previously closed at $44.46.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent research reports. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Morgan Stanley restated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Finally, Truist Financial cut their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Performance

The stock has a market cap of $10.94 billion, a price-to-earnings ratio of 60.49, a PEG ratio of 3.27 and a beta of 2.14. The company's 50 day simple moving average is $50.03 and its 200 day simple moving average is $45.10. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims & Hers Health's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $43.69, for a total value of $505,973.89. Following the completion of the transaction, the chief financial officer directly owned 116,806 shares in the company, valued at $5,103,254.14. This trade represents a 9.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Michael Chi sold 2,100 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the transaction, the insider directly owned 278,654 shares of the company's stock, valued at $16,028,178.08. This represents a 0.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,390,328 shares of company stock valued at $71,468,298 over the last 90 days. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the business. Virtus Advisers LLC acquired a new position in Hims & Hers Health in the 2nd quarter worth about $26,000. Quaker Wealth Management LLC bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at approximately $29,000. Bessemer Group Inc. increased its holdings in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after buying an additional 312 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its position in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after acquiring an additional 600 shares in the last quarter. Finally, Spire Wealth Management bought a new position in Hims & Hers Health during the second quarter valued at approximately $42,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.